Recombinant Full Length Human MAP4K5 Protein, C-Flag-tagged

• Cat.No.: MAP4K5-1433HFL
• Product Overview: Recombinant Full Length Human MAP4K5 Protein, fused to Flag-tag at C-terminus, was expressed in Mammalian cells.

Specification

• Description: This gene encodes a member of the serine/threonine protein kinase family, that is highly similar to yeast SPS1/STE20 kinase. Yeast SPS1/STE20 functions near the beginning of the MAP kinase signal cascades that is essential for yeast pheromone response. This kinase was shown to activate Jun kinase in mammalian cells, which suggested a role in stress response. Two alternatively spliced transcript variants encoding the same protein have been described for this gene.
• Source: Mammalian cells
• Species: Human
• Tag: Flag
• Form: 25 mM Tris HCl, pH 7.3, 100 mM glycine, 10% glycerol.
• Molecular Mass: 94.9 kDa
• AA Sequence: MEAPLRPAADILRRNPQQDYELVQR VGSGTYGDVYKARNVHTGELAAVKI IKLEPGDDFSLIQQEIFMVK ECKHCNIVAYFGSYLSREKLWICME YCGGGSLQDIYHVTGPLSELQIAYV CRETLQGLAYLHTKGKMHRD IKGANILLTDHGDVKLADFGVAAKI TATIAKRKSFIGTPYWMAPEVAAVE KNGGYNQLCDIWAVGITAIE LGELQPPMFDLHPMRALFLMSKSNF QPPKLKDKTKWSSTFHNFVKIALTK NPKKRPTAERLLTHTFVAQP GLSRALAVELLDKVNNPDNHAHYTE ADDDDFEPHAIIRHTIRSTNRNARA ERTASEINFDKLQFEPPLRK ETEARDEMGLSSDPNFMLQWNPFVD GANTGKSTSKRAIPPPLPPKPRISS YPEDNFPDEEKASTIKHCPD SESRAPQILRRQSSPSCGPVAETSS IGNGDGISKLMSENTEGSAQAPQLP RKKDKRDFPKPAINGLPPTP KVLMGACFSKVFDGCPLKINCATSW IHPDTKDQYIIFGTEDGIYTLNLNE LHEATMEQLFPRKCTWLYVI NNTLMSLSEGKTFQLYSHNLIALFE HAKKPGLAAHIQTHRFPDRILPRKF ALTTKIPDTKGCHKCCIVRN PYTGHKYLCGALQSGIVLLQWYEPM QKFMLIKHFDFPLPSPLNVFEMLVI PEQEYPMVCVAISKGTESNQ VVQFETINLNSASSWFTEIGAGSQQ LDSIHVTQLERDTVLVCLDKFVKIV NLQGKLKSSKKLASELSFDF RIESVVCLQDSVLAFWKHGMQGKSF KSDEVTQEISDETRVFRLLGSDRVV VLESRPTENPTAHSNLYILA
  GHENSYTRTRPLEQKLISEEDLAAN DILDYKDDDDKV
• Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining.
• Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
• Storage: Store at -80 centigrade.
• Concentration: >50 ug/mL as determined by microplate BCA method.
• Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps.
• Protein Families: Druggable Genome, Protein Kinase

Gene Information

• Gene Name: MAP4K5 mitogen-activated protein kinase kinase kinase kinase 5 [ Homo sapiens (human) ]
• Official Symbol: MAP4K5
• Synonyms: KHS; GCKR; KHS1; MAPKKKK5
• Gene ID: 11183
• mRNA Refseq: NM_198794.4
• Protein Refseq: NP_942089.1
• MIM: 604923
• UniProt ID: Q9Y4K4

Reviews

01/24/2023

Its reliability and applicability make it an invaluable tool for investigating MAP4K5 protein's expression, function, and structural characteristics.

01/26/2019

Manufacturers can enhance the research process by providing high-quality MAP4K5 protein, technical support, customization options, and potentially collaborative opportunities.

01/20/2019

The high-quality MAP4K5 protein available from manufacturers ensures consistent and reproducible results in WB experiments, making it an essential tool for researchers studying ANO2-related pathways and biological processes.

Q&As

Are there any MAP4K5-targeted therapies currently available?

As of now, MAP4K5-targeted therapies are primarily in the experimental stage, and none have been approved for clinical use.

How does MAP4K5 influence immune responses?

MAP4K5 is involved in modulating immune responses, and its dysregulation may contribute to autoimmune disorders.

How is MAP4K5 linked to neurodegenerative disorders?

MAP4K5 has been implicated in neurodegenerative disorders, and its study may provide insights into the underlying mechanisms of these conditions.

Is MAP4K5 involved in drug resistance in cancer treatment?

There is evidence suggesting that MAP4K5 may contribute to drug resistance in certain cancer types, making it an important target for overcoming resistance mechanisms.

Can MAP4K5 inhibition be personalized for different patients?

Personalized medicine approaches are being explored to tailor MAP4K5-targeted therapies based on individual patient characteristics and disease profiles.